SCHEMBL5797646

SCHEMBL5797646

COc1ccc(C(=O)Nc2cccc(-c3ccnc4c(C(=O)c5cccs5)cnn34)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDKN1A P38936 1/20 0.68
MAPK13 O15264 2/20 0.60
PIM1 P11309 2/20 0.60
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
BRAF P15056 11/20 0.56
GSK3A P49840 2/20 0.50
DAPK3 O43293 1/20 0.50
AKT1 P31749 1/20 0.50
MAPK9 P45984 1/20 0.50
NEK2 P51955 1/20 0.50
PIM3 Q86V86 1/20 0.50
PLK3 Q9H4B4 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
PPARG P37231 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
NR2E3 Q9Y5X4 1/20 0.49
NCOR2 Q9Y618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5813722 0.93 CDKN1A (0.67) CDKN1AMAPK13PIM1MEN1KMT2A
SCHEMBL5800357 0.91 CDKN1A (0.71) CDKN1AMAPK13PIM1BRAFGSK3A
SCHEMBL5808061 0.91 CDKN1A (0.66) CDKN1AMAPK13PIM1BRAFGSK3A
SCHEMBL5796947 0.90 CDKN1A (0.74) CDKN1AMAPK13PIM1BRAFGSK3A
SCHEMBL5807557 0.90 CDKN1A (0.74) CDKN1AMAPK13PIM1BRAFGSK3A
SCHEMBL5813276 0.89 CDKN1A (0.69) CDKN1AMAPK13PIM1BRAFGSK3A
SCHEMBL5796906 0.89 CDKN1A (0.71) CDKN1AMAPK13PIM1MEN1KMT2A
SCHEMBL5814280 0.89 CDKN1A (0.71) CDKN1AMAPK13PIM1MEN1KMT2A
SCHEMBL5808822 0.89 CDKN1A (0.71) CDKN1AMAPK13PIM1BRAFGSK3A
SCHEMBL5810749 0.89 CDKN1A (0.61) CDKN1AMAPK13PIM1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006033795-A2 SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH WYETH (US) 2006-03-30 WO claimed
WO-2006033796-A1 SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME WYETH (US) 2006-03-30 WO claimed
US-20060063784-A1 Method of using substituted pyrazolo [1,5-a] pyrimidines WYETH 2006-03-23 US claimed
US-20060063785-A1 Substituted pyrazolo[1,5-a] pyrimidines and process for making same WYETH 2006-03-23 US claimed
WO-2006033796-A1 SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME WYETH (US) 2006-03-30 WO disclosed
US-20060063785-A1 Substituted pyrazolo[1,5-a] pyrimidines and process for making same WYETH 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063785-A1 Substituted pyrazolo[1,5-a] pyrimidines and process for making same TYMP, DPYD, TYMS CDKN1A 28/4885MAPK13 1171/4885PIM1 586/4885
US-20060063784-A1 Method of using substituted pyrazolo [1,5-a] pyrimidines TYMP, DPYD, TYMS CDKN1A 89/4885MAPK13 1727/4885PIM1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.